-
Founded in:
1996-03-19 -
Country:
China -
Address:
No. 50, Xingang Avenue, Nanjing Economic and Technological Development Zone -
Tax NO.:
9132010060894355X2 -
Registered Funds:
173.452212 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Finasteride |
This drug belongs to the 4-nitrogen steroid hormone compound and is a specific type II 5alpha;-reductase competitive inhibitor. It inhibits the conversion of peripheral testosterone into dihydrotestosterone and reduces the levels of dihydrotestosterone in the blood, prostate, skin and other tissues. The growth, development and benign hyperplasia of the prostate depend on dihydrotestosterone. Finasteride inhibits prostate hyperplasia by reducing the levels of dihydrotestosterone in the blood and prostate tissues, and improves the related clinical symptoms of benign prostatic hyperplasia.
More
This drug belongs to the 4-nitrogen steroid hormone compound and is a specific type II 5alpha;-reductase competitive inhibitor. It inhibits the conversion of peripheral testosterone into dihydrotestosterone and reduces the levels of dihydrotestosterone in the blood, prostate, skin and other tissues. The growth, development and benign hyperplasia of the prostate depend on dihydrotestosterone. Finasteride inhibits prostate hyperplasia by reducing the levels of dihydrotestosterone in the blood and prostate tissues, and improves the related clinical symptoms of benign prostatic hyperplasia. |
5mg | 98319-26-7 | 51 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cetirizine dihydrochloride |
This product is a selective histamine H1 receptor antagonist. Animal experiments have shown that this product has no obvious anticholinergic and anti-5-hydroxytryptamine effects, is not easy to pass through the blood-cerebrospinal fluid barrier and act on the central H1 receptor. When used clinically, the central inhibitory effect is relatively mild.
More
This product is a selective histamine H1 receptor antagonist. Animal experiments have shown that this product has no obvious anticholinergic and anti-5-hydroxytryptamine effects, is not easy to pass through the blood-cerebrospinal fluid barrier and act on the central H1 receptor. When used clinically, the central inhibitory effect is relatively mild. |
83881-52-1 | 54 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Naftopidil dihydrochloride |
This product has a synergistic effect with antihypertensive drugs and diuretics, so reduce the dosage when taking them simultaneously.
More
This product has a synergistic effect with antihypertensive drugs and diuretics, so reduce the dosage when taking them simultaneously. |
57149-07-2 | 13 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Mycophenolate mofetil |
Mycophenolate mofetil (MMF) is a 2-ethyl ester derivative of mycophenolic acid (MPA). MPA is a highly effective, selective, non-competitive, and reversible inhibitor of inosine mononucleotide dehydrogenase (IMPDH), which can inhibit the classical synthesis pathway of guanine nucleotides. MPA has a highly selective effect on lymphocytes. Mycophenolate mofetil tablets are extremely effective in preventing rejection after renal transplantation and treating refractory rejection.
More
Mycophenolate mofetil (MMF) is a 2-ethyl ester derivative of mycophenolic acid (MPA). MPA is a highly effective, selective, non-competitive, and reversible inhibitor of inosine mononucleotide dehydrogenase (IMPDH), which can inhibit the classical synthesis pathway of guanine nucleotides. MPA has a highly selective effect on lymphocytes. Mycophenolate mofetil tablets are extremely effective in preventing rejection after renal transplantation and treating refractory rejection. |
115007-34-6 | 54 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Water-soluble pollen extract P5 |
Treatment of benign prostatic hyperplasia (BPH) and chronic, non-bacterial prostatitis, which may be related to blocking the conversion of testosterone into dihydrotestosterone and inhibiting the synthesis of leukotrienes and prostaglandins in the body
More
Treatment of benign prostatic hyperplasia (BPH) and chronic, non-bacterial prostatitis, which may be related to blocking the conversion of testosterone into dihydrotestosterone and inhibiting the synthesis of leukotrienes and prostaglandins in the body |
0 | ||
| Fat-soluble pollen extract EA10 |
Treatment of benign prostatic hyperplasia (BPH) and chronic, non-bacterial prostatitis, which may be related to blocking the conversion of testosterone into dihydrotestosterone and inhibiting the synthesis of leukotrienes and prostaglandins in the body
More
Treatment of benign prostatic hyperplasia (BPH) and chronic, non-bacterial prostatitis, which may be related to blocking the conversion of testosterone into dihydrotestosterone and inhibiting the synthesis of leukotrienes and prostaglandins in the body |
0 |